Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

Analyst Carter Gould of Barclays maintained a Buy rating on AbbVie (ABBV – Research Report), retaining the price target of $212.00.

With a market cap of $356.2 billion, North Chicago, Illinois-based AbbVie Inc. (ABBV) operates in the pharmaceutical sector.

vice president corporate responsibility and global philanthropy for AbbVie, a North Chicago-based pharmaceutical company, and president of the AbbVie Foundation. “The opportunity to increase ...

The new facility aims to give residents on the South Side better access to cancer care, while also attracting patients from ...

When you use links on our website, we may earn a fee. Why Trust U.S. News At U.S. News & World Report, we take an unbiased approach to our ratings. We adhere to strict editorial guidelines ...

has made a $75 million donation to the University of Chicago to support the construction of UChicago Medicine’s new cancer pavilion—the first freestanding facility in Illinois dedicated to reshaping ...

“We’re really excited and proud to have the opportunity to support University of Chicago Medicine and the South Side ...

AbbVie (NYSE:ABBV) has once again raised its full-year outlook on soaring demand for its newer immunology medicines, Skyrizi and Rinvoq. The North Chicago, Illinois-based pharma giant now expects ...

AbbVie (NYSE:ABBV) has once again raised its full-year outlook on soaring demand for its newer immunology medicines, Skyrizi ...